Tivic Health shares jump 12.44% intraday after securing BARDA meeting for Entolimod development.
ByAinvest
Tuesday, Nov 18, 2025 10:35 am ET1min read
TIVC--
Tivic Health Systems (TIVC) surged 12.44% intraday following the announcement on November 18, 2025, that it secured a meeting with BARDA to discuss Entolimod's development for acute radiation syndrome. The news highlighted Entolimod's FDA Fast Track and Orphan Drug designations, potential government partnership opportunities, and its therapeutic promise in radiation injury. The meeting is expected to clarify development pathways, fueling investor optimism about commercialization prospects. The second news item, referencing Yahoo Finance's cumulative return data dated November 14, lacked specific events to explain the intraday rally. Thus, the stock's sharp rise aligns with the BARDA-related milestone, underscoring strategic progress for the company's lead candidate.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet